Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.Load more
Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the overall mortality significantly increased by strict control of blood glucose (target HbA1c <6%) compared with a less stringent control (target HbA1c of approximately 7%). Strict glucose control resulted in a significantly higher likelihood of developing severe hypoglycaemia, while severe hypoglycaemia was itself associated with death due to CVD.Load Less
Type 2 Diabetes Mellitus
CV Outcomes in Diabetes
Risk reduction with antihyperglycemics
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).
The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.
CV specialists are well-positioned to play a key role in managing patients with T2D including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycemic agents into routine practice.
The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.
Saint Luke's America Heart Institute, Kansas City, MO, US
Mosenzon O, Wiviott SD, Cahn A, et al. Lancet Diabetes Endocrinol 2019;7:606–17.
Lingvay I, Catarig AM, Frias JP, et al. Lancet Diabetes Endocrinol 2019;7:834–44.
Fitchett D, Inzucchi, Wanner C, et al. Eur Heart J 2020;41:209–17.
Nassif ME, Windsor SL, Tang F, et al. Circulation 2019;140:1463–76.
Mahaffey KW, Jardin MJ, Bompoint S, et al. Circulation 2019;140:739–50.
Verma S, Mazer CD, Yan AT, et al. Circulation 2019;140:1693–702.
Eckel RH, Farooki A, Henry RR, et al. Clin Diabetes 2019;37:316–37.
Patorno E, Schneeweiss S, Gopalakrishnan C, et al. Diabetes Care 2019;42:2204–10.
Caruso I, Cignarelli A, Giorgino F. Trends Endocrinol Metab 2019;30:578–89.
Esser N, Zraika S. Diabetologia 2019;62:1113–22.
Mannucci E, Dicembrini I, Nreu B, Monami M. Diabetes Obes Metab 2020;22:203–11.
Hupfeld C, Mudaliar S. Diabetes Obes Metab 2019;21:1780–9.